ORGONasdaqPharmaceutical PreparationsFiscal year ends December 31
Organogenesis Holdings Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.02+0.02 (+2.03%)
Close on Oct 19, 2026
- Market cap
- $131.25M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$3.02 (−74.75%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Organogenesis Holdings Inc. grew revenue 6.5% to $457.45M over the twelve months to Jun 30, 2026. Free cash flow was $20.84M.
Revenue
$457.45M
+6.5% vs. a year earlier
Operating income
-$35.87M
TTM Q2 2026
Free cash flow
$20.84M
TTM Q2 2026
EPS, diluted
-$0.85
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $131.25M
- P/E ratio
- –
- Price to sales
- 0.29
- Price to book
- 0.89
- Dividend yield
- –
- Free cash flow yield
- 15.88%
Fundamentals
- Revenue
- $457.45M
- Net income
- -$84.16M
- EPS, diluted
- -$0.85
- Free cash flow
- $20.84M
- Book value per share
- $1.15
- Diluted shares
- 129M
Eleven years at a glance
Fiscal years 2015 to 2025 and trailing twelve months, USD
Revenue
$457.45M+6.5% YoY
Gross profit
–
Operating income
-$35.87M
Net income
-$84.16M
EPS, diluted
-$0.85
Free cash flow
$20.84M
Reported periodTrailing twelve months